Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion

Key facts

Sponsor

Chinese Academy of Sciences

Intervention

Computer-Aided Diagnosis System for Preoperative Prediction of MVI in HCC(diagnostic_test)

Enrollment

400 enrolled

Eligibility

18-18 years · All sexes

Timeline

2025 – 2027

Study locations (19)

• Meng Chao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China
• Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China
• Zhujiang Hospital, Guangzhou, Guangdong, China
• Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, Guangdong, China
• Zhuhai People's Hospital, Zhuhai, Guangdong, China
• First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
• Guizhou Provincial People's Hospital, Guiyang, Guizhou, China
• Henan Provincial People's Hospital, Zhengzhou, Henan, China
• Shengjing Hospital, Shenyang, Liaoning, China
• West China Hospital, Chengdu, Sichuan, China
• Dazhou Central Hospital, Dazhou, Sichuan, China
• First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
• The First People's Hospital of Yunnan Province, Kunming, Yunnan, China
• Yunnan Cancer Hospital, Kunming, Yunnan, China
• First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
• +4 more locations on ClinicalTrials.gov

Collaborators

Peking Union Medical College Hospital · First Affiliated Hospital of Kunming Medical University · Beijing YouAn Hospital · Zhujiang Hospital · Meng Chao Hepatobiliary Hospital of Fujian Medical University · First Affiliated Hospital of Wenzhou Medical University · Fifth Affiliated Hospital, Sun Yat-Sen University · Henan Provincial People's Hospital · Guangdong Provincial Hospital of Traditional Chinese Medicine · Shengjing Hospital · Beijing Tsinghua Changgeng Hospital · Yunnan Cancer Hospital · The First People's Hospital of Yunnan · Guizhou Provincial People's Hospital · First Affiliated Hospital of Guangxi Medical University · West China Hospital · ZhuHai Hospital · Dazhou Central Hospital · Eastern Hepatobiliary Surgery Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Fibrolamellar hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07521852
  A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
  TaiRx, Inc.
• RECRUITINGPHASE2NCT07504471
  Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases
  Ruijin Hospital
• RECRUITINGNCT07295275
  Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection
  West China Hospital
• RECRUITINGPHASE2NCT07324824
  Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
  Sun Yat-sen University
• RECRUITINGEARLY PHASE1NCT07193862
  Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
  Northwell Health
• RECRUITINGPHASE1, PHASE2NCT07282184
  Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
  Tongji Hospital
• RECRUITINGPHASE2NCT07099274
  Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE2NCT05690048
  Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)
  Michael Dill

See all trials for Fibrolamellar hepatocellular carcinoma →